PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer

Lignende værker

• Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
  af: Ordonez, Liliana D., et al.
  Udgivet: (2019)
• PARP Inhibition in BRCA-Mutant Breast Cancer
  af: Turk, Anita, et al.
  Udgivet: (2018)
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
  af: Rottenberg, Sven, et al.
  Udgivet: (2008)
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
  af: Johnson, Neil, et al.
  Udgivet: (2013)
• Enhancement of synthetic lethality via combinations of ABT-888 (a PARP inhibitor) and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models
  af: Clark, Caroline C., et al.
  Udgivet: (2012)